Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep

Vaccine

Volumn 25, Issue 4, 2007, Pages 672-678

  Boone, Josh D ^a   Balasuriya, Udeni B ^a   Karaca, Kemal ^b   Audonnet, Jean Christophe ^b   Yao, Jiansheng ^c   He, Ling ^c   Nordgren, Robert ^b   Monaco, Federica ^d   Savini, Giovanni ^d   Gardner, Ian A ^e   MacLachlan, N James ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Sanofi Pasteur   (Canada)

^d ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELL ABRUZZO E DEL MOLISE G CAPORALE   (Italy)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bluetongue; Canarypox virus; Sheep; Vaccine

Indexed keywords

CAPSID PROTEIN; LIVE VACCINE; NEUTRALIZING ANTIBODY; PROTEIN VP2; PROTEIN VP5; RECOMBITEK; VIRUS VECTOR; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLUETONGUE ORBIVIRUS; CANARYPOX VIRUS; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; FEVER; GENE EXPRESSION; IMMUNOGENICITY; INFECTION PREVENTION; LYMPHOCYTOPENIA; MALE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SEROTYPE; SHEEP; SHEEP DISEASE; TREATMENT RESPONSE; VACCINATION; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIREMIA; VIRUS RECOMBINANT; VIRUS STRAIN; WEST NILE FLAVIVIRUS;

ANIMALS; BLUETONGUE; BLUETONGUE VIRUS; CANARYPOX VIRUS; CAPSID PROTEINS; FEMALE; GENE EXPRESSION REGULATION, VIRAL; MALE; SHEEP; TIME FACTORS; VIRAL VACCINES;

EID: 33845344012     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.08.025     Document Type: Article

References (43)

1. Verwoerd D., and Erasmus B.J. Bluetongue. In: Coetzer J.A., and Tustin R.C. (Eds). Infectious diseases of livestock. 2nd ed. (2004), Oxford University Press, Cape Town 1201-1230
2. Spreull J. Malarial catarrhal fever (bluetongue) of sheep in South Africa. J Comp Pathol 18 (1905) 321-337
3. Gibbs E.P.J., and Greiner E.C. The epidemiology of bluetongue. Comp Immunol Microbiol Infect Dis 17 (1994) 207-220
4. Tabachnick W.J. Culicoides genetics: implications for understanding the global epidemiology of bluetongue virus infection. Vet Ital 40 (2004) 145-150
5. Alexander G.I., Alexander M.P., and St. George T.D. Bluetongue-its impact on international trade in meat and livestock. In: St. George T.D., and Kegao P. (Eds). Bluetongue disease in Southeast Asia and the Pacific (1996), ACIAR, Canberra 254-258
6. Purse B.V., Mellor P.S., Rogers D.J., Samuel A.R., Mertens P.P., and Baylis M. Climate change and the recent emergence of bluetongue in Europe. Nat Rev Microbiol 3 (2005) 171-181
7. Bayliss M., and Mellor P. Bluetongue around the Mediterranean in 2001. Vet Rec 149 (2001) 659
8. Mertens P.P., Brown F., and Sangar D.V. Assignment of the genome segments of bluetongue virus type 1 to the proteins they encode. Virology 135 (1984) 207-217
9. DeMaula C.D., Bonneau K.R., and MacLachlan N.J. Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. Virus Res 67 (2000) 59-66
10. Huismans H., van der Walt N.T., Cloete M., and Erasmus B.J. Isolation of a capsid protein of bluetongue virus that induces a protective immune response in sheep. Virology 157 (1987) 172-179
11. Roy P., Urakawa T., Van Dijk A.A., and Erasmus B.J. Recombinant virus vaccine for bluetongue disease in sheep. J Virol 64 (1990) 1998-2003
12. Lobato Z.I., Coupar B.E., Gray C.P., Lunt R., and Andrew M.E. Antibody responses and protective immunity to recombinant vaccinia expressed-expressed bluetongue virus antigens. Vet Immunol Immunopathol 59 (1997) 293-309
13. Roy P., French T., and Erasmus B.J. Protective efficacy of virus-like particles for bluetongue disease. Vaccine 10 (1992) 28-32
14. Roy P., Bishop D.H., LeBlois H., and Erasmus B.J. Long-lasting protection of sheep against bluetongue challenge after vaccination with like-like particles: evidence for homologous and partial heterologous protection. Vaccine 12 (1994) 805-811
15. Gomez-Trejedor C. Brief overview of the bluetongue situation in Mediterranean Europe, 1998-2004. Vet Ital 40 (2004) 57-60
16. Panagiotatus D.E. Regional overview of bluetongue viruses, vectors, surveillance and unique features in Eastern Europe between 1998 and 2003. Vet Ital 40 (2004) 61-72
17. Patta C., Giovannini A., Rolesu S., Nannini D., Savini G., Calistri P., et al. Bluetongue vaccination in Europe: the Italian experience. Vet Ital 40 (2004) 601-610
18. Dungu B., Gerdes T., and Smit T. The use of vaccination in the control of bluetongue in southern Africa. Vet Ital 40 (2004) 616-622
19. Flanagan M., and Johnson S.J. The effects of vaccination of Merino ewes with an attenuated Australian bluetongue virus serotype 23 at different stages of gestation. Aust Vet J 72 (1996) 455-457
20. MacLachlan N.J., Osburn B.I., Stott J.L., and Ghalib H.W. Orbivirus infection of the bovine fetus. Prog Clin Biol Res 178 (1985) 79-84
21. Venter G.J., Gerdes G.H., Mellor P.S., and Paweska J.T. Transmission potential of South African Culicoides species for live-attenuated bluetongue virus. Vet Ital 40 (2004) 198-202
22. Ferrari G., De Liberato C., Scavia G., Loenzetti R., Zini M., Farina M., et al. Active circulation of bluetongue vaccine virus serotype-2 among unvaccinated cattle in central Italy. Prev Vet Med 68 (2005) 103-113
23. Veronesi E., Hamblin C., and Mellor P.S. Live attenuated bluetongue virus vaccine viruses in Dorset poll sheep, before and after passage in vector midges (Diptera: Ceratopogonidae). Vaccine 23 (2005) 5509-5516
24. Bonneau K.R., DeMaula C.D., Mullens B.A., and MacLachlan N.J. Duration of viraemia infectious to Culicoides sonorensis in bluetongue virus-infected cattle and sheep. Vet Microbiol 88 (2002) 115-125
25. DeMaula C.D., Leutenegger C.M., Bonneau K.R., and MacLachlan N.J. The role of endothelial cell derived inflammatory and vasoactive mediators in the pathogenesis of bluetongue. Virology 296 (2002) 330-337
26. Bonneau K.R., Mullens B.A., and MacLachlan N.J. Occurrence of genetic drift and founder effect during quasispecies evolution of the VP2 and NS3/3A genes of bluetongue virus upon passage between sheep, cattle and Culicoides sonorensis. J Virol 75 (2001) 8298-8305
27. Bonneau K.R., Zhang N., Zhu J., Zhang F., Li Z., Zhang K., et al. Sequence comparison of the L2 and S10 gene segments of bluetongue viruses from the United States and the People's Republic of China. Virus Res 61 (1999) 153-160
28. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., et al. Recombinant canarypox virus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 18 (2004) 221-230
29. Piccini A., Perkus M.E., and Paoletti E. Vaccinia virus as an expression vector. Methods Enzymol 153 (1987) 545-563
30. MacLachlan N.J., Heidner H.W., and Fuller F.J. Humoral immune response of calves to bluetongue virus infection. Am J Vet Res 48 (1987) 1031-1035
31. Whetter L.E., Gebhard D.H., and MacLachlan N.J. Temporal appearance of structural and nonstructural bluetongue viral proteins in infected cells, as determined by immunofluorescence staining and flow cytometry. Am J Vet Res 51 (1990) 1174-1179
32. Richards R.G., MacLachlan N.J., Heidner H.W., and Fuller F.J. Comparison of virological and serological responses of lambs and calves infected with bluetongue virus serotype 10. Vet Microbiol 18 (1988) 233-242
33. Beaty B.J., Calisher C.H., and Shope R.E. Arboviruses. In: Emmons N.J., and Schmidt R.W. (Eds). Diagnostic procedures for viral, rickettsial and chlamydial infections. 6th ed. (1989), American Public Health Association, Washington 797-855
34. Ostlund E.N., Crom R.L., Pedersen D.D., Johnson D.J., Williams W.O., and Schmitt B.J. Equine West Nile encephalitis, United States. Emerg Infect Dis 7 (2001) 665-669
35. Murray P.K., and Eaton B.T. Vaccines for bluetongue. Aust Vet J 73 (1996) 207-210
36. Roy P. Genetically engineered structure-based vaccine for bluetongue disease. Vet Ital 40 (2004) 594-600
37. Stott J.L., Barber T.L., and Osburn B.I. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res 46 (1985) 1043-1049
38. Di Emidio B., Nicolussi P., Patta C., Ronchi G.F., Monaco F., Savini G., et al. Efficacy and safety studies on an inactivated vaccine against bluetongue virus serotype 2. Vet Ital 40 (2004) 640-644
39. Savini G., Monaco F., Facchinei A., Pinoni C., Salucci S., Cofini F., et al. Field vaccination of sheep with bivalent modified-live vaccine against bluetongue virus serotypes 2 and 9: effect on milk production. Vet Ital 40 (2003) 627-630
40. Potgieter A.C., Monaco F., Mangan O., Nomikou K., Yadin H., and Savini G. VP2 segment sequence analysis of some isolates of bluetongue virus recovered in the Mediterranean Basin during the 1998-2003 outbreak. J Vet Med B 52 (2005) 372-379
41. Monaco F., Camma C., Serini S., and Savini G. Differentiation between field and vaccine strains of bluetongue virus serotype 16. Vet Microbiol 116 (2006) 43-52
42. Toulemonde C.E., Daly J., Sindle T., Guigal P.M., Audonnet J.C., and Minke J.M. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 156 (2005) 367-371
43. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., et al. Efficacy of canarypox virus-vectored vaccine against feline leukaemia. Vet Rec 153 (2003) 141-145